Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma

BACKGROUND: Hyaluronic acid (HA) promotes cancer metastasis; however, the currently approved treatments do not target HA. Metastatic renal carcinoma (mRCC) is an incurable disease. Sorafenib (SF) is a modestly effective antiangiogenic drug for mRCC. Although only endothelial cells express known SF t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiaojiao, Jordan, Andre R., Zhu, Huabin, Hasanali, Sarrah L., Thomas, Eric, Lokeshwar, Soum D., Morera, Daley S., Alexander, Sung, McDaniels, Joseph, Sharma, Anuj, Aguilar, Karina, Sarcan, Semih, Zhu, Tianyi, Soloway, Mark S., Terris, Martha K., Thangaraju, Muthusamy, Lopez, Luis E., Lokeshwar, Vinata B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801563/
https://www.ncbi.nlm.nih.gov/pubmed/36581895
http://dx.doi.org/10.1186/s12935-022-02818-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801563/
https://www.ncbi.nlm.nih.gov/pubmed/36581895
http://dx.doi.org/10.1186/s12935-022-02818-1

Ejemplares similares